An in-depth venom proteomics of *Hydrophis curtus* (spine-bellied sea snake) from Penang Island, Malaysia is reported and correlated with the toxicity of the major toxins, as well as their in vivo cross-neutralization using the Sea Snake Antivenom produced for *Hydrophis schistosus*. This study provides important insights into the diversity and variability of sea snake venom protein composition, and how antivenom manufacturing and use can be optimized.

1. Introduction {#sec1-toxins-11-00003}
===============

The Elapidae family of venomous snakes consists of approximately 369 species in \>60 genera ([www.reptile-database.org](www.reptile-database.org)). A basal split in their phylogeny circa 10.1--24.3 Mya gave rise to the recent divergence of Australo-Melanesian elapids, resulting in two distinct subfamilies: (1) Elapinae, consisting of the paleogeographically-related Asian, African and American elapids; (2) Hydrophiinae, comprising the Australo-Melanesian elapids \[[@B1-toxins-11-00003],[@B2-toxins-11-00003]\]. The Hydrophiinae represents a diverse paraphyletic clade that rapidly radiates in and around Australia, producing lineages that were well adapted to terrestrial or aquatic habitats \[[@B2-toxins-11-00003]\]. The aquatic elapids, generally referred to as sea snakes, form a large group of marine reptiles. It comprises the basal, semi-aquatic sea kraits (*Laticauda* sp., 6 species) and the more derived, densely complex true sea snakes (\>50 species). The genus *Hydrophis* constitutes the core group of the true sea snakes. It is considered as a monophyletic clade by consensus today \[[@B3-toxins-11-00003]\].

*Hydrophis* sea snakes live their entire lives in the water, and some of the species are often part of the by-catch of fishermen in areas where they occur. Sea snake bite typically occurs among the fishermen while removing sea snakes entangled in their fishing nets---a classic scenario described in most sea snake bite literature \[[@B4-toxins-11-00003],[@B5-toxins-11-00003]\], although treading on a sea snake in shallow estuaries has also been reported as a cause \[[@B6-toxins-11-00003],[@B7-toxins-11-00003]\]. In Southeast Asia, sea snake envenoming is increasingly an occupational health hazard that has expanded its threat beyond the fishing community. In this part of the world, sea snakes are a significant part of the global wildlife trade \[[@B8-toxins-11-00003]\], where they are captured, bred and harvested for live snake parts used in the production of accessories, and for food (sea snake meat as an exotic delicacy), as well as for medicinal use (tonic soup, snake wine, gall bladder as traditional medicament). The increased human contact with sea snakes from these anthropogenic activities poses a threat to a wider community of people. Although sea snake bites are infrequently reported, envenoming is fatal, and early treatment may be missed as the bite is painless \[[@B9-toxins-11-00003]\]. Clinically, patients envenomed by the common beaked sea snake (*Hydrophis schistosus*, or *Enhydrina schistosa*) develop neuromuscular paralysis and systemic myotoxicity complicated by acute kidney injury \[[@B10-toxins-11-00003],[@B11-toxins-11-00003]\]. The pathophysiology of *H. schistosus* envenoming has been correlated with the presence of alpha-neurotoxins and basic phospholipases A~2~ in the venom \[[@B12-toxins-11-00003],[@B13-toxins-11-00003],[@B14-toxins-11-00003]\], while the envenomation by other sea snake species is commonly assumed to follow a similar mechanism. As sea snakes are highly adapted to their ecological niche, their venoms are thought to be "biochemically simple", with a composition that is strictly diet-driven to subdue fast-moving prey (fish). The streamlined nature of sea snake venoms and the link to their ichthyophagous dietary simplicity have been shown earlier in an extensive liquid chromatography-mass spectrometry (LC/MS) analysis of Colubroidea snake venoms \[[@B15-toxins-11-00003]\]. Indeed, a handful of venom proteomic studies of sea snakes and a sea krait were in agreement that alpha-neurotoxins and phospholipases A~2~ form the dominant proteins in these venoms \[[@B12-toxins-11-00003],[@B16-toxins-11-00003],[@B17-toxins-11-00003],[@B18-toxins-11-00003],[@B19-toxins-11-00003],[@B20-toxins-11-00003]\]. The highly streamlined "minimalist" venom proteomes, however, does not limit the diversity of the toxins: the molecular subtypes, relative abundances and functionality (including toxic activities) of the venom proteins could still vary \[[@B14-toxins-11-00003],[@B19-toxins-11-00003],[@B21-toxins-11-00003],[@B22-toxins-11-00003]\]. This provides the rationale for continuous investigation into the venom proteomes of different sea snake species in order to understand the intra-genus and intra-species diversity and evolution of the toxins. The knowledge will pave the path for in-depth exploration of venom antigenic properties, which is crucial for the optimization of antivenom production technique in the region \[[@B23-toxins-11-00003]\].

Currently, the only definitive antidote treatment for sea snake envenoming is the Sea Snake Antivenom (SSAV) produced by Seqirus (previously CSL, Australia) against *Hydrophis schistosus*, using venom sourced from Penang Island, Malaysia. This antivenom has been shown to be effective in vitro in preventing neuromuscular depressant activity induced by the venoms of several sea snakes and a sea krait \[[@B24-toxins-11-00003]\]. In vivo, SSAV was able to protect mice from the lethal effect of *H. schistosus*, *Hydrophis platura*, *Aipysurus laevus* and *Laticauda colubrina* venoms to various extents \[[@B12-toxins-11-00003],[@B17-toxins-11-00003],[@B18-toxins-11-00003],[@B19-toxins-11-00003]\]. To elucidate the limiting factors of antivenom efficacy, the principal toxins, namely the subtypes of alpha-neurotoxins and phospholipases A~2~ in *H. schistosus* and *L. colubrina* venoms, have been further purified and tested for toxin-specific neutralization \[[@B19-toxins-11-00003],[@B25-toxins-11-00003]\]. The in vivo cross-neutralization of SSAV against the venoms and principal toxins of other sea snake species that are medically relevant and widely distributed, e.g., the spine-bellied sea snake (*Hydrophis curtus*), remains to be further examined.

In the Gulf of Thailand, it was reported that one of the main species involved in the catch and trade industry is the spine-bellied sea snake \[[@B8-toxins-11-00003]\]---named for the multiple small spiny protrusion on its ventral scales over the abdominal region ([Figure 1](#toxins-11-00003-f001){ref-type="fig"}). This species was previously placed within the genus *Lapemis*, which is now incorporated into the core *Hydrophis* group, and is known as *H. curtus* (Shaw's sea snake) or *Hydrophis hardwickii* (Hardwick's sea snake), although *H. hardwickii* is commonly considered to be a synonym of *H. curtus* or a subspecies of *H. curtus*. *Hydrophis curtus* has extensive distribution form the Persian Gulf to the Indian coastline, Myanmar, Thailand, Straits of Malacca, Strait of Taiwan, South China Sea, the Philippines, Indonesia, Papua New Guinea, and northern and eastern Australia (<http://reptile-database.reptarium.cz/>). This is also a species commonly encountered by fishermen in the western coast of Peninsular Malaya \[[@B26-toxins-11-00003]\], as with the beaked sea snake, *H. schistosus* (author CHT's observation). Recently, the venom proteome of *H. curtus* from Australian waters (Weipa) has been reported. It shows a venom profile rich in alpha-neurotoxins, phospholipases A~2~ and cysteine-rich venom proteins, along with some high molecular weight proteins and a number of regulatory or cellular proteins \[[@B20-toxins-11-00003]\]. In the present study, using a decomplexing proteomic approach, the venom proteome of *H. curtus* from Penang (Malaysia) was characterized for insights into the geographical variation of the venom. The in vivo toxicity and the antigenic properties of the major toxins of this species were also investigated, and the venom functionality was elucidated in correlation with the venom proteome. In addition, the in vivo efficacy of the heterologous antivenom, SSAV, was also examined for cross-neutralization and immunorecognition for *H. curtus* venom proteins, including the principal lethal toxins.

2. Results {#sec2-toxins-11-00003}
==========

2.1. Decomplexation Proteomics of Penang H. curtus Venom {#sec2dot1-toxins-11-00003}
--------------------------------------------------------

*H. curtus* venom was resolved by C18 reverse-phase high-performance liquid chromatography (HPLC) into 10 protein fractions as assigned in [Figure 1](#toxins-11-00003-f001){ref-type="fig"}. Fractions 1, 5, 6 and 9 were the major fractions, constituting \>90% total venom proteins (estimation made by peaks area). SDS-PAGE showed that fractions 1--3 contained proteins of low molecular mass (\<10 kDa), whereas Fractions 4, 5, 6 and 8 contained proteins of 12--15 kDa ([Figure 1](#toxins-11-00003-f001){ref-type="fig"}). Moderate to high molecular weight proteins eluted later (beyond 150 min of HPLC): Fraction 9 contained a protein of approximately 26 kDa, while Fraction 10 was heterogeneous with multiple proteins (25--100 kDa). There was no protein band observed in Fraction 7. The SDS-PAGE of the whole venom revealed that the proteins of 12--15 kDa formed the bulk of the venom proteins (\~60% by densitometry), followed by proteins of \<10 kDa (\~30%) and 26 kDa (\~10%), consistent with the HPLC profile and the overall SDS-PAGE of the venom fractions ([Figure 1](#toxins-11-00003-f001){ref-type="fig"}).

2.2. Proteome of Penang H. curtus Venom {#sec2dot2-toxins-11-00003}
---------------------------------------

The HPLC fractions of venom proteins were further identified by LCMS/MS and data-mining through a non-redundant NCBI protein dataset (taxonomy: Serpentes, taxid: 8570) and an in-house venom-gland transcriptomic database. [Table 1](#toxins-11-00003-t001){ref-type="table"} documents the identified and categorized proteins according to the corresponding HPLC fractions. In the table, relevant information on the protein profiling, including the protein abundances (% total venom proteins), accession numbers, protein scores and numbers of matched tryptic peptides is shown. Data generated via the tandem mass spectrometry (MS/MS) e.g., the ionic mass/charge ratios and tryptic peptide sequences, were compiled in [Supplementary File Table S1](#app1-toxins-11-00003){ref-type="app"}.

A total of 41 distinct proteins (toxins and non-toxins) were identified from *H. curtus* venom ([Table 2](#toxins-11-00003-t002){ref-type="table"}). The majority of the proteins identified (26 out of 41) were annotated to database sequences shared by the same species (*H. curtus* or *H. hardwickii*). In total, 98.6% of the venom proteins were composed of toxins clustered into 10 families (comprising 30 identifiable toxins). Of these, phospholipase A~2~ (PLA~2~, 62.0%) dominated the proteome. Within the PLA~2~ family, the acidic subtypes were more abundant than the basic subtypes (5:1 ratio). The protein abundance was followed by three-finger toxin (3FTX, 26.33%) and cysteine-rich secretory protein (CRiSP, 9.0%). The 3FTX proteins consisted of short neurotoxin (SNTX, one subtype) as its major component (22.89%), while the long neurotoxins (LNTX, 3 subtypes) were less abundant (3.44%). A variety of toxins of low abundances (\<0.5% each) were also identified, including snake venom metalloproteinase, L-amino acid oxidase, Ophiophagus venom factor, waprin, phosphodiesterase, phospholipase A~2~ inhibitor and phospholipase B ([Figure 2](#toxins-11-00003-f002){ref-type="fig"}). Approximately 11 non-toxin proteins or 1.4% of the venom proteins were regulatory or cellular proteins.

The proteomic profile of the Malaysian *H. curtus* venom (current study) was further tabulated in [Table 3](#toxins-11-00003-t003){ref-type="table"} in comparison with venomic data reported previously for other sea elapids.

2.3. Immunoreactivity Profiling of H. curtus Venom Proteins {#sec2dot3-toxins-11-00003}
-----------------------------------------------------------

[Figure 3](#toxins-11-00003-f003){ref-type="fig"} shows the immunoreactivity of SSAV toward the different venom fractions (10 ng protein) of *H. curtus*, the holovenoms of *H. curtus*, *Notechis scutatus*, *H. schistosus* and *C. rhodostoma*. The binding activity of SSAV (reflected by the absorbance on ELISA) toward *H. curtus* and *N. scutatus* venoms were high (Abs \>1.0) but marginally lower toward *H. schistosus* venom. The negative control, *C. rhodotoma* venom, exhibited weak binding by SSAV (Abs \~0.1). Among the protein fractions, Fraction 6 (containing the major PLA~2~ proteins) immunoreacted most strongly with SSAV (Abs \~1.0). Fractions 1 (SNTX), 4 and 5 (PLA2) showed moderate immunoreactivity (Abs: 0.6--0.7), whereas Fractions 2, 3 (LNTX) and 7 (non-toxin components) were relatively weak in their immunoreactivity (Abs \~0.3). SSAV binding activity toward proteins in Fractions 8 (non-toxin), 9 (CRISP) and 10 (enzymes, inhibitors and non-toxin components) were considerably low, with average absorbance values of \<0.2.

2.4. Toxicity of H. curtus Venom and Principal Toxins {#sec2dot4-toxins-11-00003}
-----------------------------------------------------

The Malaysian *H. curtus* venom was lethal in mice with an intravenous LD~50~ of 0.20 (0.18--0.24) µg/g. The SNTX (F1) and LNTX (F3) were both lethal, and the SNTX appeared to be more toxic (LD~50~ = 0.10 µg/g) than LNTX (LD~50~ = 0.24 µg/g). Screening of toxicity for all other fractions including the major fractions F4 and F6 which contained primarily PLA~2~, as well as F9 which contained CRISP, showed that these proteins were non-lethal in mice at a dose \>1 µg/g.

2.5. Cross-Neutralization of H. curtus Venom and Toxins by SSAV {#sec2dot5-toxins-11-00003}
---------------------------------------------------------------

In neutralization assay, SSAV cross-neutralized the whole venom effectively at a potency of 2.03 mg/mL (amount of venom completely neutralized by one milliliter of antivenom), equivalent to the normalized potency of 9.35 mg/g (amount of venom or toxin neutralized by one gram of antivenom protein). SSAV cross-neutralized the principal toxins i.e., SNTX and LNTX to different extents: the normalized potency values against SNTX and LNTX were 1.57 mg/g and 3.50 mg/g, respectively. All challenge doses (venom and toxins) were standardized at 5 LD~50~. The neutralization parameters i.e., median effective doses (ED~50~), median effective ratio (ER~50~), potency (P) and normalized potency (n-P) are shown in [Table 4](#toxins-11-00003-t004){ref-type="table"}.

3. Discussion {#sec3-toxins-11-00003}
=============

C18 reverse-phase HPCL and gel electrophoresis revealed a common trend of venom profiles between *Hydrophis curtus* and related venomous marine snakes. This is consistent with the perceived "streamlining of venom" as an adaptive feature for predation in the aquatic environment, where fish is the main targeted prey. The venom chromatograms of *H. curtus* (current study) and its monophyletic cousin *H. schistosus* \[[@B12-toxins-11-00003]\] both showed well resolved, less complex protein peaks in the following regions (based on an optimized venom-decomplexing protocol) \[[@B27-toxins-11-00003]\]: 30--35 min, 60--75 min and 90--120 min, which corresponded to the elution of SNTX, LNTX and PLA~2~, respectively. The similar pattern of protein elution was reported for virtually all sea elapid venom profiles (using reverse-phase column), and the three toxin groups typically constitute the bulk of the venom proteins at \>95% (by weight), although the individual protein subtypes and their individual expression could vary substantially at the inter- and intra-specific levels. Compared to *H. schistosus,* which has a more specialized diet (feeding mainly on tachysurus catfish), *H. curtus* is known to be generalistic, and a greater complexity of venom proteins is probably needed to subdue and digest different types of prey. This might be reflected in the more diverse protein types/subtypes and variable protein expression in *H. curtus* venom compared to *H. schistosus* profile at the subproteomic level.

On the whole, the venom proteomes of the congeneric *Hydrophis* sp. (*H. curtus*, *H. schistosus*, *H. platurus*, *H cyanocinctus*) and the paraphyletic *A. laevus* showed that 3FTX were invariably alpha-neurotoxins of short- and/or long-chain proteoforms (SNTX and LNTX). Alpha-neurotoxins are post-synaptic antagonists of post-junctional nicotinic acetylcholine receptors (nAChR); blockade of neurotransmission caused by these NTX can lead to neuromuscular paralysis, respiratory failure and death \[[@B28-toxins-11-00003],[@B29-toxins-11-00003]\]. SNTX are generally more reversible than LNTX in receptor binding (inactivation of nAChR), but they are less well neutralized in vivo by commercial antivenoms, as shown in several toxin-specific neutralization studies \[[@B25-toxins-11-00003],[@B30-toxins-11-00003],[@B31-toxins-11-00003]\]. The abundance of SNTX appears to be a limiting factor of antivenom efficacy (in neutralizing the venom toxicity), and this has an implication on antivenom production, i.e., that elapid antivenom efficacy should be improved by optimizing the formulation of toxin immunogen, taking into account the poorly neutralized neurotoxins. The Malaysian *H. curtus* venom (the object of the current study) has more SNTX than LTNX (SNTX:LNTX ratio of 10:1); this SNTX-predominating trend in the subproteome is observed in the congeneric *H. schistosus* (SNTX:LNTX \~4:1), *H. platura* (SNTX:LNTX \~2:1), *H. cyanocinctus* (SNTX:LNTX \~2:1), and the paraphyletic *A. laevus* which venom contained only SNTX \[[@B12-toxins-11-00003],[@B16-toxins-11-00003],[@B17-toxins-11-00003],[@B18-toxins-11-00003]\]. On the other hand, the semi-marine *L. colubrina* (Bali) has more LNTX than SNTX (LNTX:SNTX \~3:1) in its venom \[[@B19-toxins-11-00003]\], probably a feature related to its strict diet of eels. This could be an indicator for the evolutionary status of *L. colubrina* being basal to all other lineages, including the Australasian terrestrial elapids and the fully marine hydrophids nested within \[[@B21-toxins-11-00003]\]. The three-finger neurotoxin profile is typically much more diverse in the terrestrial counterparts e.g., cobras \[[@B32-toxins-11-00003]\], kraits \[[@B33-toxins-11-00003]\] and coral snakes \[[@B34-toxins-11-00003],[@B35-toxins-11-00003]\] but highly streamlined to SNTX in the hydrophids \[[@B12-toxins-11-00003],[@B17-toxins-11-00003]\].

In the recently published venom proteome of *H. curtus* sourced from Weipa (Northern Australia), the alpha-NTX profile varied between two catches (January batch with body length \>600 mm vs. June batch with body length \<400 mm) \[[@B20-toxins-11-00003]\]. In the January catch, that was categorized as adults (*n* = 10), the alpha-neurotoxins were predominantly LNTX (LNTX:SNTX \~3:1), whereas LNTX and SNTX were equally abundant in the June catch (subadults, *n* = 10) (LNTX:SNTX \~1:1). The profiles reported previously were varied from the current study in terms of the neurotoxin diversity and the ratio of SNTX to LNTX. The reverse-phase HPLC and the LCMS/MS data of *H. curtus* venoms also varied between the previous and the current studies. Notably, the first chromatographic peak (corresponding to SNTX elution) was remarkably much higher (with a larger AUC) followed by significantly lower peaks (10-fold smaller) of LNTX in the Malaysian sample, whereas in the Australian specimen, the main fractions containing LNTX (Fractions 2 and 3) showed comparable peak heights with its SNTX-containing Fraction 1 \[[@B20-toxins-11-00003]\]. It was also noted that the neurotoxins (in particular LNTX) in the Australian *H. curtus* venom samples eluted across all chromatographic fractions (Fractions 1--11) in the previous study; this makes comparison on the elution pattern and protein abundance of NTX between different chromatograms rather challenging. The inconsistent resolution of NTX could be due to the different type of column materials used: the C18 column used in the present and most other venomic studies has a longer hydrocarbon chain bonded to the silica (as octadecylsilane); this packing material is inherently more hydrophobic and has a longer retention time for proteins compared to the C4 column. On reducing SDS-PAGE, the profiling of protein fractions (by molecular weights) from C18 reverse-phase HPLC (current study) was highly consistent with the protein identification by LCMS/MS for all fractions. Comparison of SDS-PAGE profiles for the venoms and corresponding HPLC fractions between the Malaysian and the Australian *H. curtus* was precluded, as the SDS-PAGE of Australian specimen was not available. Nonetheless, the proteomes reported thus far illustrate the remarkable variability of the highly evolved neurotoxins between the two geographical *H. curtus* populations.

Despite the differences in their 3FTX (neurotoxin) profile, PLA~2~ is consistently the most dominant proteins in the venoms of the Malaysian (\>60%, current study) and the Australian *H. curtus* (55--67%) \[[@B20-toxins-11-00003]\]. This phenomenon was also seen in *A. laevus* venom, in which PLA~2~ constituted \>70% of the total venom proteins. The PLA~2~ dominance in these species is "balanced" with a lower 3FTX abundance, as shown in the Malaysian *H. curtus* (\~26%, current study) and the Australian *A. laevus* (\~25%) \[[@B18-toxins-11-00003]\], although the Australian *H. curtus* venom contained a slightly higher abundance of 3FTX (30--40%) \[[@B20-toxins-11-00003]\]. This venomic phenotype contrasts with the venom proteomes reported previously for the other core *Hydrophis* sea snakes (*H. cyanocinctus*, *H. schistosus* and *H. platurus*) \[[@B12-toxins-11-00003],[@B16-toxins-11-00003],[@B17-toxins-11-00003]\], as well as the taxonomically-divergent *L. colubrina* \[[@B19-toxins-11-00003]\], in which three-finger alpha-neurotoxins are dominant (50--81%). The unique subproteomic variability of *H. curtus* venom delineates a potential NTX-PLA~2~ dichotomy among the *Hydrophis* sea snakes, which should be further verified when more sea snake venom proteomes become available. The variable expression of neurotoxins and PLA~2~ presumably correlates with the venom neurotoxic and myotoxic activities, supporting the relationship between snake venom compositions and feeding adaptations in different niches. Clinically, the relatively lower alpha-neurotoxins abundance and higher PLA~2~ content imply that the pathophysiology of *H. curtus* envenoming possibly varies from other sea snake species that demonstrate a neurotoxin-predominating venom composition. Considering their high abundances, the PLA~2~ likely play a crucial role in the toxic activity of *H. curtus* venom. However, PLA~2~ is pharmacologically diverse \[[@B36-toxins-11-00003]\], and the high number of PLA~2~ subtypes within the venom indicates that the PLA~2~ functionality is complex. In *H. curtus*, the predominating PLA~2~ are of acidic subtypes which were probably not as effective as sea snake basic PLA~2~ at penetrating the membrane phospholipids to cause cytotoxicity and myotoxicity \[[@B11-toxins-11-00003],[@B37-toxins-11-00003]\]. The high acidic:basic PLA~2~ proportion in the Malaysian *H. curtus* venom proteome (4:1) is in line with proportions reported for the Australian *H. curtus* (3:1, 7:1) \[[@B20-toxins-11-00003]\] and *A. laevus* (2:1) \[[@B18-toxins-11-00003]\], but opposite to the Malaysian *H. schistosus* (1:4) \[[@B12-toxins-11-00003]\] and the Balinese *L. colubrina,* whose venom virtually composed of basic PLA~2~ (acidic PLA~2~ was only present in a trace amount) \[[@B19-toxins-11-00003]\]. Although it is generally well accepted that the basic PLA~2~ proteins contribute more substantially to venom lethality than acidic PLA~2~, the biological activities of the different PLA~2~ proteoforms (acidic or basic) can vary between snake species. The PLA~2~ activity may or may not be clinically important, as shown in several acidic or even basic PLA~2~ that are non-lethal from elapid venoms \[[@B19-toxins-11-00003],[@B25-toxins-11-00003],[@B31-toxins-11-00003]\]. In studies of sea snake venom, the equivocal toxicity of PLA~2~ could be further elucidated with isolated toxin study (discussed below) to correlate with the clinical or epidemiological findings. In most sea snake envenoming, however, *H. curtus* bite has not been well identified and documented.

The diversity and the dominating proportion of *H. curtus* venom proteins in this study also differed from a previous work that studied cDNA libraries cloned from venom-gland mRNA of *H. curtus* (*Lapemis curtus*) sampled from Weipa, Australia \[[@B21-toxins-11-00003]\]. The venom gene transcription appeared to bias toward 3FTX (43.4%) compared to PLA~2~ (9.8%), contrasting with the established venom proteome of this species (regardless of Weipa or Penang origin) in which PLA~2~ dominated (PLA~2~ \> 3FTX, by total venom proteins). The incongruence between venom-gland transcriptome and venom proteome of snake has been well documented in several other species, such as the monocled cobra \[[@B38-toxins-11-00003]\] and king cobra \[[@B39-toxins-11-00003]\], indicating that there is significant post-transcription regulation and/or post-translational modification in the synthesis of snake venom proteins.

The cysteine-rich secretory protein (CRiSP) family contributes to a relatively high protein abundance in the Malaysian *H. curtus* venom. CRiSP was reported in the proteomes of virtually all sea snake venoms except for *H. cyanocinctus* \[[@B16-toxins-11-00003]\], where its absence could be due to a lower detection sensitivity of mass spectrometry and instrument used previously. The abundance of CRiSP in the Malaysian *H. curtus* venom is consistent with that reported for the adult *H. curtus* (Weipa) and *A. laevus* (Broome). CRiSP exhibits diverse biological activities such as the inhibition of smooth muscle contraction, blockade of cyclic nucleotide-gated ion channel, and hypothermia in animals \[[@B40-toxins-11-00003],[@B41-toxins-11-00003]\]. Clinically, the pathophysiological role of CRiSP in snakebite in humans is still unclear, and is worthy of further investigation. Characterization of the novel CRiSP from the Malaysian *H. curtus* venom is highly feasible in view of the abundance and purity of the protein (judged by its homogeneity on SDS-PAGE) eluted using the current HPLC protocol.

Other proteins present in the venom proteome were minor components (on average \<1% each). The variety of these minor proteins, interestingly, is greater than in other sea elapids reported so far. The sea snake venom [l]{.smallcaps}-amino acid oxidase (LAAO) enzyme was detected proteomically for the second time in sea elapids, after the first report in the *H. schistosus* venom proteome \[[@B12-toxins-11-00003]\]. This finding implies that LAAO could be a trace enzyme that exists in at least two species of the core *Hydrophis* genus, enriching our knowledgebase and demonstrating that sea snake venoms are not totally devoid of LAAO \[[@B42-toxins-11-00003]\].

The detection of snake venom metalloproteinase (SVMP) in the Malaysian *H. curtus* venom is consistent with what had been observed in the venom proteomes of the Australian *H. curtus* and the Malaysian *H. schistosus* \[[@B12-toxins-11-00003],[@B20-toxins-11-00003]\]. The contents of SVMP in the Malaysian *H. curtus* and *H. schistosus* were, however, markedly higher than the Australian *H. curtus*. As these were the four sea snake venom samples shown to contain SVMP thus far, it is uncertain whether the distribution of SVMP in sea snakes is geographically related. Besides, the Malaysian *H. curtus* venom contains phosphodiesterase, phospholipase B, Ophiophagus venom factor and waprin and this is the first report of the presence of these proteins in the venom proteomes of sea snakes, although weak phosphoesterase enzymatic activity had been reported previously from *Lapemis hardwickii* (*H. curtus*) venom \[[@B43-toxins-11-00003]\]. The roles of these minor proteins in the venom remain to be further investigated.

In the in vivo toxicity test, *H. curtus* venom showed an approximately 2-fold higher LD~50~ compared to *H. schistosus* (LD~50~ = 0.07 µg/g) and *L. colubrina* (0.10 µg/g). In line with the current proteomic findings, the lower lethality of *H. curtus* venom is driven by its lower 3FTX content (alpha-neurotoxins, 26.33%) in contrast to the more lethal *H. schistosus* venom (alpha-neurotoxins, 70.5%; myotoxic PLA~2~, \~20%) and *L. colubrina* (alpha-neurotoxins, 66.14%) \[[@B12-toxins-11-00003],[@B19-toxins-11-00003]\]. Considering the relative abundances of *H. curtus* SNTX (\~22.89%) and LNTX (\~3.44%), in one unit of LD~50~ of the whole venom (0.2 µg/g mouse), there are approximately 0.046 µg SNTX and 0.007 µg LNTX, which represent 46% and 2.9% of the LD~50~ of the neurotoxin subtypes, respectively. This indicates that SNTX and LNTX may work in synergism, contributing to the whole venom lethality, and antivenom treatment should seek to address effective neutralization of these specific principal toxins. On the other hand, the major PLA~2~ fractions in *H. curtus* venom lacked lethal activity; however, the potential myotoxic properties of the various PLA~2~ isoforms deserve further investigation in the future. On the whole, the sea snake venoms appeared to share similarities in their profiles and toxicity. In view of their relatively recent radiation and close phylogenetic relatedness, it is anticipated that substantial antigenicity is conserved among the different sea snake species. This immunological property of antigenicity sharing is medically important, as it would allow the use of SSAV (raised against the Malaysian *H. schistosus* venom) in cross-neutralizing the toxicity of different sea snake venoms. Earlier, in a nerve-muscle preparation, SSAV (1 unit/mL) added at t~90~ (time at which 90% inhibition of initial twitch height occurred) was able to reverse the inhibition of twitches (20--50%) produced by *H. curtus* venom \[[@B24-toxins-11-00003]\]. In agreement with the in vitro findings, the present study further confirmed that SSAV was effective in vivo in cross-neutralizing the lethality of the Malaysian *H. curtus* venom. The normalized potency of SSAV against *H. curtus* (P = 9.35 mg/g) was in fact much higher than the previously reported potencies for *H. schistosus* (P = 2.21 mg/g) \[[@B25-toxins-11-00003]\] and *Laticauda colubrina* (P = 5.01 mg/g) \[[@B19-toxins-11-00003]\]. This could be due to the higher LD~50~ of *H. curtus* venom---at a challenge dose of 5 LD~50~, the neutralization could be interpreted as having more venom proteins being neutralized per unit antivenom. When examining the specific principal toxins, it was found that SSAV potency in neutralizing SNTX did not differ markedly among *H. schistosus*, *H. curtus* and *L. colubrina* (n-P = 1.2--1.5 mg/g) \[[@B19-toxins-11-00003],[@B25-toxins-11-00003]\]. The neutralization of LNTX, however, varied to some extent (normalized potency was approximately 2--6 mg/g) among these species. The finding implies a conserved repertoire of SNTX epitopes among the species. The LNTX epitopes, on the other hand, seemed to be more variable, and the potency level of neutralization followed the homology of *H. schistosus* \> *H. curtus* \> *L. colubrina*. On toxin-specific neutralization, it is evident that SSAV exhibited better neutralization against LNTX than SNTX, indicating that SNTX is a limiting factor of antivenom efficacy. This phenomenon has also been reported in the neutralization of alpha-neurotoxins of several *Naja* cobra species (by cobra antivenoms) \[[@B25-toxins-11-00003],[@B30-toxins-11-00003],[@B31-toxins-11-00003]\]. Further research is needed for the improvement of elapid antivenom formulation through strategies that aim to enhance the toxin immunogenicity and broaden the species coverage in the region \[[@B23-toxins-11-00003]\].

The sharing of protein antigens between *H. curtus* and *H. schistosus* is further supported by the comparable immunoreactivity of SSAV toward both venoms. As the core hydrophids are a group of relatively young marine radiation of the elapids \[[@B3-toxins-11-00003]\], the extent of amino acid substitution/divergence and protein neofunctionalization might be rather limited within the clade, hence the highly conserved protein antigenicity. The strong immunoreactivity of SSAV toward the venom of *N. scutatus* (Australian tiger snake), however, is inconsistent with the very different venom compositions (proteomes) between *N. scutatus* and *H. schistosus* \[[@B12-toxins-11-00003],[@B44-toxins-11-00003]\]. The phenomenon could be partly explained by the fact that *N. scutatus* venom was included in the immunogen mix as a strategy to enhance the anti-titer level in SSAV production \[[@B44-toxins-11-00003]\]. This observed strong immunoreactivity also supported the cross-neutralization of *N. scutatus* venom toxicity by SSAV previously \[[@B44-toxins-11-00003]\]. On fraction-based ELISA, the strong binding of PLA~2~ and SNTX by SSAV indicates that the anti-titer against these proteins was high, presumably due to the higher abundance of these toxins in the venom (collectively \> 90% of total proteins) used in immunization. Although SSAV neutralized LNTX more effectively than it neutralized SNTX, SSAV exhibited stronger immunoreactivity toward SNTX than to LNTX. This conflicting observation implies that the immunological binding activity of antivenom to toxins does not necessarily always correlate with the in vivo neutralization activity of antivenom. Hence, the neutralization capability and potency of antivenom against specific toxins should be tested in vivo in addition to in vitro immunological assays when studying antivenomics \[[@B45-toxins-11-00003],[@B46-toxins-11-00003]\].

4. Conclusions {#sec4-toxins-11-00003}
==============

The venom proteome of Malaysian (Penang) *H. curtus* shows a minimalistic toxin arsenal that is dominated by PLA~2~ and 3FTX (composed of only short and long alpha-neurotoxins). The highly streamlined venom protein repertoire of the various *Hydrophis* sp. illustrates the case of molecular economy of toxins, which is an evolutionary solution convergently adopted by various sea snake taxa (including Laticaudinae) in response to the need for a fast moving, fish-based diet in the marine habitat. In comparison with the other marine/semi-marine species, *H. curtus* venom is unique, as there are more abundant and more diverse PLA~2~ than 3FTX (at a ratio of \~3:1) in the proteome. The major toxin distribution accounts for the higher LD~50~ of the venom, as its toxicity is mainly driven by the short alpha-neurotoxins (the diverse PLA~2~ were non-lethal). Subproteomic toxin variability within *H. curtus* of allopatric populations is apparent. The 3FTX of Malaysian *H. curtus* venom (Penang) comprised of mainly short neurotoxin, whereas the Australian specimens (Weipa) had more long-chain neurotoxins. The venom protein antigenicity was well conserved between *H. curtus* and the phylogenetically related *H. schistosus* (and *Notechis scutatus*) used in the production of SSAV, rendering the antivenom able to immunorecognize and in vivo cross-neutralize *H. curtus* venom effectively. The weak neutralization of short neurotoxin remains a limiting factor of antivenom efficacy in neutralization. Optimizing the immunogen formulation of alpha-neurotoxins may improve the efficacy of antivenom to neutralize NTX-predominating snake venoms.

5. Materials and Methods {#sec5-toxins-11-00003}
========================

5.1. Samples and Chemicals {#sec5dot1-toxins-11-00003}
--------------------------

*Hydrophis curtus* venom was a pooled sample from 10 adult snakes collected in the waters of Penang Island (Malaysia). The antivenom tested was Sea Snake Antivenom (SSAV) produced by CSL Ltd. (Melbourne, Australia, Seqirus Ltd. currently). The antivenom was in (liquid form) contained F(ab')~2~ from horses hyperimmunized against the venoms of *Hydrophis schistosus* (beaked sea snake, obtained from the waters of Penang Island, Malaysia) and the Australian *Notechis scutatus* (common tiger snake). The protein concentration of the antivenom was 217.2 ± 3.0 mg/mL, determined in a previous study from the laboratory \[[@B25-toxins-11-00003]\].

The chemicals and reagents used were primarily supplied by Sigma-Aldrich (Saint Louis, MO, USA) and were of analytical grade. The molecular weight marker Spectra™ Multicolor Broad Range Protein Ladder (10--260 kDa), trypsin (mass spectrometry grade), HPLC grade acetonitrile (ACN) and trifluoroacetic acid (TFA) were purchased from Thermo Scientific™ Pierce™ (Waltham, MA, USA). Millipore ZipTip^®^ C~18~ Pipette Tips and LiChrospher^®^ WP 300 RP-18 (5 µm) were supplied by Merck (Burlington, MA, USA).

5.2. Reverse-Phase High Performance Liquid Chromatography {#sec5dot2-toxins-11-00003}
---------------------------------------------------------

Two milligrams of *H. curtus* venom were reconstituted in MilliQ ultrapure water and fractionated using a reverse-phase column (LiChrospher^®^ WP 300 C~18~ column, Merck Millipore, Burlington, MA, USA) via a high performance liquid chromatography system (Shimadzu LC-20AD, Shimadzu, Tokyo, Japan). The flow rate of mobile phase was set to 1 mL/min over a course of 180 min. Stepwise linear gradients of mobile phase composed of 0.1% TFA in water (Solvent A) and 0.1% TFA in 100% ACN (Solvent B) were used for protein elution as follow: 0--5% B for 10 min, 5--15% B for 20 min, 15--45% B for 120 min and 45--70% B over 20 min. The elution of protein was monitored at 215 nm. The protein fractions were collected manually, lyophilized and stored at −20 °C until use.

5.3. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) {#sec5dot3-toxins-11-00003}
--------------------------------------------------------------------------

The freeze-dried protein fractions collected from C18 reverse-phase HPLC were dissolved in MilliQ ultrapure water and further fractionated by electrophoresis on a 15% gel under reducing conditions. Coomassie Brilliant Blue stained the protein bands in each HPLC fractions on the gel. Spectra™ Multicolor Broad Range Protein Ladder (10 to 260 kDa) served as a standard for calibrating molecular weights of proteins.

5.4. In-Solution Protein Digestion with Trypsin {#sec5dot4-toxins-11-00003}
-----------------------------------------------

Fractionated proteins collected from the reverse-phase were reduced by DTT (Dithiothreitol), alkylated with IAA (iodoacetamide) and subjected to in-solution proteolytic digestion with trypsin according to the method reported previously \[[@B47-toxins-11-00003]\]. Millipore ZipTip^®^ C~18~ Pipette Tips (Merck, Burlington, MA, USA) were used to clean up and desalt the trypsin-digested peptides for an enhanced performance of mass spectrometry analysis.

5.5. Nano-ESI-LCMS/MS of the Tryptic Digests and Label-Free LCMS/MS Protein Quantitation {#sec5dot5-toxins-11-00003}
----------------------------------------------------------------------------------------

The digested and desalted *H. curtus* venom peptides were analyzed using a nano-ESI LCMS/MS system (Agilent 1200 HPLC-Chip/MS Interface coupled with Agilent 6520 Accurate-Mass Q-TOF LC/MS, Agilent Technologies, Palo Alto, CA, USA). The peptides were loaded in a 300 Å C~18~, enrichment column (injection volume = 1 μL) followed by a 75 μm × 150 mm analytical column (Agilent N° G4240-62010). 0.1% formic acid in water (A) and 90% acetonitrile in water with 0.1% formic acid (B) were used for elution of the peptides at the following stepwise linear gradients: 3--50% B for 30 min, 50--95% B for 2 min, and 95% B for 5 min. The ion polarity was set to positive ionization mode. The temperature of the drying gas was 325 °C and the flow rate was 5 L/min. The fragmentor voltage and capillary voltage were set to 175 V and 1995 V, respectively. The ion spectra were acquired in an MS/MS mode where a MS scan range of 110--3000 *m*/*z* and a MS/MS scan range of 50--3000 *m*/*z* were used. Precursor charges were selected based on double- and triple-charged states but excluding the reference ions i.e., 922.0098 *m*/*z* (z = 1) and 121.0509 (z = 1). Data within the MH^+^ mass range of 600--4000 Da was obtained and processed with Agilent Spectrum Mill MS Proteomics Workbench software packages. A single modification was selected for the carbamidomethylation of cysteine. The peptide masses were searched against a non-redundant protein sequence database from NCBI (taxonomy: Serpentes, taxid: 8570) and an in-house transcriptomic database comprising elapid species of *Hydrophis curtus*, *Hydrophis schistosus, Ophiophagus hannah*, *Calliophis intestinalis*, *Bungarus caeruleus* and *Naja naja*. The identification of protein was validated using the following parameters: protein score \>11, peptides score \>6, scored peak intensity (SPI) \>60%. The protein abundances were estimated through HPLC and ESI-LCMS/MS as previously described \[[@B47-toxins-11-00003],[@B48-toxins-11-00003]\]. In brief, the relative abundance of an individual protein within a chromatographic fraction was estimated by its relative spectral intensity from LCMS/MS. The protein's relative abundance in term of percentage of total venom proteins was then determined by multiplying its relative spectral intensity and its chromatographic peak area under the curve (AUC), as described previously.

5.6. Median Lethal Dose of Venom/Toxin and Efficacy of Neutralization by Antivenom {#sec5dot6-toxins-11-00003}
----------------------------------------------------------------------------------

The venom proteins were injected intravenously into ICR mice via tail vein (20--25 g, *n* = 4 per dose, 4 doses). The mice were monitored and allowed free access to food and water ad libitum. The survival ratio of mice was recorded at 24 h. Neutralization assay was conducted as described previously \[[@B48-toxins-11-00003]\]. A challenge dose of the venom proteins at 5 LD~50~ was mixed with various doses of Sea Snake Antivenom (SSAV) in normal saline and pre-incubated at 37 °C for 30 min, followed by tail vein injection (20--25 g, *n* = 4 per dose, 4 doses). The mice were allowed access to food and water ad libitum and the survival ratio was recorded at 24 h. Animal experiments were conducted according to the CIOMS guidelines \[[@B49-toxins-11-00003]\]. Ethics clearance was given by the Institutional Animal Care and Use Committee, Faculty of Medicine, University of Malaya (Ethical approval code: 2016-190607/TCH/R/PHARM, Date of approval: 7 June 2016).

5.7. Immunological and Antigenic Profiling of H. curtus Venom Fractions {#sec5dot7-toxins-11-00003}
-----------------------------------------------------------------------

The immunoreactivity of Sea Snake Antivenom (SSAV) toward the HPLC protein fractions of *H. curtus* venom was examined using an indirect enzyme-linked immunosorbent assay (ELISA) as described previously \[[@B26-toxins-11-00003]\]. The venoms of *H. schistosus* and *N. scutatus* were used as positive controls, while *Calloselasma rhodostoma* (Malayan pit viper) venom served as negative control. Immunoplate wells were each pre-coated with 10 ng proteins of the venom or venom protein fractions overnight at 4 °C. The plate was then flicked dry and rinsed three times with phosphate-buffered saline containing 0.5% Tween^®^20 (PBST). The protein concentrations of SSAV were prepared at 20 mg/mL, and 100 µL of SSAV in 1:900 PBST dilution was added to each pre-coated well, followed by 1 h incubation at room temperature. After washing the plate three times with PBST, 100 µL of appropriately diluted horseradish peroxidase-conjugated anti-horse-IgG (Jackson ImmunoResearch Inc., West Grove, PA, USA) in PBST (1:10000) was added to the well, followed by 1 h incubation at room temperature. The excess residues were washed away with PBST then. One hundred microliters of substrate solution (0.5 mg/mL o-phenylenediamine and 0.003% hydrogen peroxide in 0.1 M citrate-phosphate buffer, pH 5.0) was freshly prepared and added to each well. The enzymatic reaction took place in the dark for 30 min at room temperature. The reaction was then terminated by adding 50 µL of 12.5% sulphuric acid, and the absorbance at 490 nm was read against the blank using a multiplate reader (Molecular Devices-VersaMax^TM^, Sunnyvale, CA, USA). Values were means ± standard error mean (SEM) of triplicate experiments.

5.8. Statistical Analyses {#sec5dot8-toxins-11-00003}
-------------------------

The median lethal dose (LD~50~), median effective dose (ED~50~, the amount of reconstituted antivenom in µL that protects 50% of the animals tested), effective dose ratio (ER~50~, the amount of venom in mg neutralized per mL antivenom at which 50% of envenomed mice survived) and the 95% confidence intervals (C.I.) were calculated using the Probit analysis \[[@B50-toxins-11-00003]\]. The potency of antivenom (P, defined as the amount of venom or toxin completely neutralized by a unit volume of antivenom, mg/mL), and the normalized potency values (n-P, defined as the amount of venom or toxin completely neutralized by a unit amount of antivenom, mg/g) were determined according to Tan et al. \[[@B51-toxins-11-00003]\]. The statistical analysis package used was the BioStat analysis software (2008 v5.2.5, AnalystSoft Inc., Vancouver, BC, Canada).

The authors are grateful for Evan SH Quah and CH Tan for sharing sea snake images.

The following is available online at <http://www.mdpi.com/2072-6651/11/1/3/s1>, Table S1: Mass spectrometry results of venom from *Hydrophis curtus* (Penang, Malaysia).

###### 

Click here for additional data file.
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![(**A**) Spine-bellied sea snake, *Hydrophis curtus* from Penang Island, Malaysia. (**B**) Protruding spine-like structures on the ventral scales of the snake. (**C**) Lyophilized *H. curtus* venom in whitish crystalline form. (**D**) Decomplexation of *H. curtus* (Penang, Malaysia) venom with C18 reverse-phase HPLC. (**E**) 15% SDS-PAGE of *H. curtus* venom and its HPLC fractions under reducing conditions. L: Protein markers; C: Whole venom. Numbers indicate HPLC fractions.](toxins-11-00003-g001){#toxins-11-00003-f001}

![Venom proteome of the spine-bellied sea snake, *Hydrophis curtus* from Penang Island, Malaysia. Percentages indicate relative protein abundance by total venom proteins.](toxins-11-00003-g002){#toxins-11-00003-f002}

![Immunoprofiling of *H. curtus* venom and protein fractions by the heterologous Sea Snake Antivenom. F1--F10: Reverse-phase HPLC of *H. curtus* venom; HC: *H. curtus* venom; NS: *Notechis scutatus* venom; HS: *Hydrophis schistosus* venom; CR: *Calloselasma rhodostoma* venom.](toxins-11-00003-g003){#toxins-11-00003-f003}

toxins-11-00003-t001_Table 1

###### 

Protein identification of Malaysian (Penang) *Hydrophis curtus* venom by ESI-LCMS/MS of C18 reverse-phase HPLC following in-solution tryptic digestion.

  Fraction   Distinct Peptides   MS/MS Search Score   Species (as Per Annotation in Database)   Database Accession ^a^   Protein Name (as Per Annotation in Database)    Relative Abundance (%) ^b^
  ---------- ------------------- -------------------- ----------------------------------------- ------------------------ ----------------------------------------------- ----------------------------
  1          2                   28.12                *Hydrophis curtus*                        P68416                   Short neurotoxin 1                              22.89
  2          3                   62.47                *Hydrophis curtus*                        A3FM53                   Long neurotoxin 2                               0.49
  3          5                   114.27               *Hydrophis curtus*                        Q8UW29                   Long neurotoxin 1                               1.10
             4                   84.14                *Hydrophis curtus*                        A3FM53                   Long neurotoxin 2                               1.32
             2                   40.42                *Ophiophagus hannah*                      Q53B58                   Long neurotoxin OH-55                           0.33
             1                   21.62                *Ophiophagus hannah*                      Q53B57                   Long neurotoxin OH-56                           0.21
  4          5                   92.36                *Hydrophis curtus*                        Q8UW31                   Acidic phospholipase A~2~ 57                    0.08
             2                   46.47                *Enhydrina schistosa*                     Unigene22561_ESM         Acidic phospholipase A~2~ 57                    0.34
             2                   43.43                *Hydrophis curtus*                        CL4079.Contig1_HCM       Basic phospholipase A~2~ 73                     0.07
             2                   35.82                *Calliophis intestinalis*                 CL2932.Contig3_CIM       Acidic phospholipase A~2~ 57                    0.16
             3                   66.02                *Enhydrina schistosa*                     P00610                   Basic phospholipase A~2~                        0.45
             2                   50.61                *Hydrophis curtus*                        Q8UW30                   Basic phospholipase A~2~ 73                     0.32
             1                   20.76                *Hydrophis curtus*                        Unigene14087_HCM         Waprin-Rha1                                     0.11
  5          4                   85.11                *Enhydrina schistosa*                     P00610                   Basic phospholipase A~2~                        2.90
             3                   64.58                *Hydrophis curtus*                        Q8UW08                   Basic phospholipase A~2~                        1.68
             3                   60.39                *Hydrophis curtus*                        Q8UW30                   Basic phospholipase A~2~ 73                     2.78
             2                   46.67                *Enhydrina schistosa*                     Unigene22561_ESM         Acidic phospholipase A~2~ 57                    1.80
             2                   45.14                *Naja Naja*                               CL339.Contig1_NNSL       Basic phospholipase A~2~                        2.85
             3                   47.42                *Hydrophis curtus*                        Q8UW31                   Acidic phospholipase A~2~ 57                    0.48
             2                   31.85                *Bungurus caeruleus*                      Unigene17389_BCSL        Acidic phospholipase A~2~ 57                    0.05
             2                   24.1                 *Calliophis intestinalis*                 CL2932.Contig3_CIM       Acidic phospholipase A~2~ 57                    0.15
  6          7                   131.08               *Hydrophis curtus*                        Q8UW31                   Acidic phospholipase A~2~ 57                    28.11
             2                   46.96                *Hydrophis curtus*                        Q8UW08                   Basic phospholipase A~2~                        0.98
             2                   42.22                *Enhydrina schistosa*                     P00610                   Basic phospholipase A~2~                        0.80
             2                   41.03                *Bungarus caeruleus*                      Unigene17389_BCSL        Acidic phospholipase A~2~ 57                    15.26
             2                   38.92                *Hydrophis curtus*                        Q8UW30                   basic phospholipase A~2~ 73                     0.91
             2                   31.08                *Denisonia devisi*                        R4G2S8                   PLA-2-Den-2                                     1.82
  7          13                  242.58               *Hydrophis curtus*                        CL2848.Contig2_HCM       Extracellular matrix protein 1                  0.16
  8          8                   143.01               *Hydrophis curtus*                        CL2323.Contig2_HCM       Lysozyme C, milk isozyme-like                   0.77
  9          8                   148.33               *Hydrophis curtus*                        Q8UW11                   Cysteine-rich venom protein 2                   3.28
             6                   111.6                *Enhydrina schistosa*                     CL131.Contig1_ESM        Cysteine-rich secretory protein                 3.42
             3                   51.38                *Hydrophis curtus*                        Q8UW25                   Cysteine-rich venom protein 1                   1.49
  10         23                  394.95               *Ophiophagus hannah*                      P81383                   L-amino-acid oxidase                            0.18
             20                  351.67               *Hydrophis curtus*                        Unigene7803_HCM          Transferrin                                     0.15
             12                  197.37               *Ophiophagus hannah*                      I2C090                   Ophiophagus venom factor                        0.06
             8                   139.98               *Ophiophagus hannah*                      CL304.Contig1_OHM        OVF precursor protein                           0.05
             9                   144.94               *Hydrophis curtus*                        CL4561.Contig1_HCM       Glutathione peroxidase 3                        0.07
             8                   138.68               *Enhydrina schistosa*                     CL1665.Contig1_ESM       Sulfhydryl oxidase 1-like                       0.07
             7                   124.2                *Hydrophis curtus*                        Q8UW11                   Cysteine-rich venom protein 2                   0.81
             7                   122.36               *Hydrophis curtus*                        CL4690.Contig9_HCM       Phospholipase A2 inhibitor                      0.20
             6                   89.52                *Ovophis okinavensis*                     U3TDL2                   glutaminyl_cyclase                              0.02
             4                   69.73                *Hydrophis curtus*                        Unigene19328_HCM         Phospholipase A2 inhibitor beta                 0.25
             4                   54.96                *Hydrophis curtus*                        CL2048.Contig1_HCM       Multiple inositol polyphosphate phosphatase 1   0.05
             3                   46.73                *Hydrophis curtus*                        CL1278.Contig2_HCM       Phospholipase B                                 0.02
             3                   45.91                *Enhydrina schistosa*                     CL560.Contig2_ESM        Carinatease-1                                   0.09
             2                   37.92                *Hydrophis curtus*                        CL4690.Contig1_HCM       Scutatease-1                                    0.22
             2                   35.54                *Hydrophis curtus*                        Unigene390_HCM           Zinc metalloproteinase-disintegrin-like NaMP    0.05
             2                   36.44                *Enhydrina schistosa*                     CL79.Contig2_ESM         ADP-ribosyl cyclase 1                           0.01
             2                   34.29                *Enhydrina schistosa*                     CL98.Contig1_ESM         Lysosomal Pro-X carboxypeptidase-like           0.04
             2                   32.92                *Hydrophis curtus*                        Unigene20804_HCM         Phosphodiesterase                               0.04
             2                   32.47                *Hydrophis curtus*                        CL1263.Contig2_HCM       Golgi apparatus protein 1                       0.02
             2                   30.78                *Hydrophis curtus*                        Unigene23143_HCM         N-acetylglucosamine-6-sulfatase                 0.02
             2                   29.28                *Ophiophagus hannah*                      CL2083.Contig1_OHM       OVF precursor protein                           0.03

^a^ Protein codes with suffix "\_HCM", "\_ESM", "\_OHM", "\_CIM", "\_BCSL" and "\_NNSL" were derived from the in-house database containing RNAseq specific for the following: HCM: Malaysian *Hydrophis curtus*; ESM: Malaysian *Hydrophis schistosus*; OHM: Malaysian *Ophiophagus hannah*; CIM: Malaysian *Calliophis intestinalis*; BCSL: Sri Lankan *Bungarus caeruleus*; NNSL: Sri Lankan *Naja naja*. ^b^ Protein abundance was interpreted as the percentage of total venom proteins. Cysteine residues determined in MS/MS analysis are carbamidomethylated. Protein identifications were validated with the following filters: protein score \>11, peptides score \>6 and scored peak intensity (SPI) \>60%. The relative abundance of an individual protein was estimated based on its relative spectral intensity within an HPLC fraction and the chromatographic peak area under the curve (AUC).

toxins-11-00003-t002_Table 2

###### 

Overview of Malaysian (Penang) *Hydrophis curtus* venom proteome by protein families and subtypes with relative abundances (%).

  Protein Family/Protein Subtype                   Fraction   Accession Code ^a^   Relative Abundance (%) ^b^
  ------------------------------------------------ ---------- -------------------- ----------------------------
  **Phospholipases A~2~**                                                          **62.00**
  **Acidic PLA~2~**                                                                **48.26**
   Acidic phospholipase A~2~ 57                    4,5,6      Q8UW31               28.68
   PLA-~2~-Den-2                                   6          R4G2S8               1.82
   Acidic phospholipase A~2~ 57                    5,6        Unigene17389_BCSL    15.31
   Acidic phospholipase A~2~ 57                    4,5        Unigene22561_ESM     2.15
   Acidic phospholipase A~2~ 57                    4,5        CL2932.Contig3_CIM   0.31
  **Basic PLA~2~**                                                                 **13.74**
   Basic phospholipase A~2~                        4,5,6      P00610               4.15
   Basic phospholipase A~2~                        5,6        Q8UW08               2.66
   Basic phospholipase A~2~ 73                     4,5,6      Q8UW30               4.01
   Basic phospholipase A~2~                        5          CL339.Contig1_NNSL   2.85
   Basic phospholipase A~2~ 73                     4          CL4079.Contig1_HCM   0.07
  **Three-finger toxins**                                                          **26.33**
  **Short Neurotoxin**                                                             **22.89**
   Short neurotoxin 1                              1          P68416               22.89
  **Long Neurotoxin**                                                              **3.44**
   Long neurotoxin 2                               2,3        A3FM53               1.81
   Long neurotoxin OH-56                           3          Q53B57               0.21
   Long neurotoxin OH-55                           3          Q53B58               0.33
   Long neurotoxin 1                               3          Q8UW29               1.10
  **Cysteine-rich secretory protein**                                              **9.00**
   Cysteine-rich venom protein 2                   9,10       Q8UW11               4.09
   Cysteine-rich venom protein 1                   9          Q8UW25               1.49
   Cysteine-rich secretory protein                 9          CL131.Contig1_ESM    3.42
  **Phospholipase A~2~ inhibitors**                                                **0.45**
   Phospholipase A~2~ inhibitor beta               10         Unigene19328_HCM     0.25
   Phospholipase A~2~ inhibitor                    10         CL4690.Contig9_HCM   0.20
  **Snake venom metalloproteinases**                                               **0.36**
   Zinc metalloproteinase-disintegrin-like NaMP    10         Unigene390_HCM       0.05
   Scutatease-1                                    10         CL4690.Contig1_HCM   0.22
   Carinatease-1                                   10         CL560.Contig2_ESM    0.09
  **L-amino acid oxidase**                                                         **0.18**
   L-amino-acid oxidase                            10         P81383               0.18
  **Ophiophagus venom factor**                                                     **0.14**
   Ophiophagus venom factor                        10         I2C090               0.06
   OVF precursor protein                           10         CL304.Contig1_OHM    0.05
   OVF precursor protein                           10         CL2083.Contig1_OHM   0.03
  **Waprin**                                                                       **0.11**
   Waprin-Rha1                                     4          Unigene14087_HCM     0.11
  **Phosphodiesterase**                                                            **0.04**
   Phosphodiesterase                               10         Unigene20804_HCM     0.04
  **Phospholipase B**                                                              **0.02**
   Phospholipase B                                 10         CL1278.Contig2_HCM   0.02
  **Non-toxin**                                                                    **1.38**
   Extracellular matrix protein 1                  7          CL2848.Contig2_HCM   0.16
   Lysozyme C, milk isozyme-like                   8          CL2323.Contig2_HCM   0.77
   Transferrin                                     10         Unigene7803_HCM      0.15
   Glutathione peroxidase 3                        10         CL4561.Contig1_HCM   0.07
   Sulfhydryl oxidase 1-like                       10         CL1665.Contig1_ESM   0.07
   Glutaminyl_cyclase                              10         U3TDL2               0.02
   Multiple inositol polyphosphate phosphatase 1   10         CL2048.Contig1_HCM   0.05
   ADP-ribosyl cyclase 1                           10         CL79.Contig2_ESM     0.01
   Lysosomal Pro-X carboxypeptidase-like           10         CL98.Contig1_ESM     0.04
   Golgi apparatus protein 1                       10         CL1263.Contig2_HCM   0.02
   N-acetylglucosamine-6-sulfatase                 10         Unigene23143_HCM     0.02

^a^ Protein codes with suffix "\_HCM", "\_ESM", "\_OHM", "\_CIM", "\_BCSL" and "\_NNSL" were derived from the in-house database containing RNAseq specific for the following: HCM: Malaysian *Hydrophis curtus*; ESM: Malaysian *Hydrophis schistosus*; OHM: Malaysian *Ophiophagus hannah*; CIM: Malaysian *Calliophis intestinalis*; BCSL: Sri Lankan *Bungarus caeruleus*; NNSL: Sri Lankan *Naja naja*. ^b^ Protein abundance was interpreted as the percentage of total venom proteins.

toxins-11-00003-t003_Table 3

###### 

Venom proteomic profiles of sea elapids (sea snakes and sea krait). Values indicate the relative abundances of the proteins (by total venom protein).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Species                            *H. curtus* (Penang)\                    *H. curtus* (January, Weipa)\                    *H. curtus* (June, Weipa)\                      *H. schistosus* (Penang)\                      *L. colubrina* (Bali)\                              *Aipysurus laevus* (Broome)\                       *H. platura* (Costa Rica)\                         *H. cyanocinctus* (Hara)\
                                     *n* = 10 Adults\                         *n* = 11 Adults                                  *n* = 10 Subadults                              *n* = 10 Adults                                *n* = Several                                       *n* = 4                                            *n* = 84                                           *n* = Several
                                     Dry Weight Per Milking: \~1--8 mg                                                                                                                                                                                                                                                                                                                  
  ---------------------------------- ---------------------------------------- ------------------------------------------------ ----------------------------------------------- ---------------------------------------------- --------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------
  **i.v. LD~50~ (µg/g mouse)**       0.20 (0.18--0.24)                        NA                                               NA                                              0.07 (0.05--0.09)                              0.10 (0.08--0.12)                                   0.15 (0.08--0.25)                                  0.23\                                              0.132
                                                                                                                                                                                                                                                                                                                                     (note: 0.13 by i.p. route)                         

  **Reference**                      Current study                            Neale et al. (2017) \[[@B20-toxins-11-00003]\]   Tan et al. (2015b) \[[@B12-toxins-11-00003]\]   Tan et al. (2017) \[[@B19-toxins-11-00003]\]   Laustsen et al. (2015) \[[@B18-toxins-11-00003]\]   Lomonte et al. (2014) \[[@B17-toxins-11-00003]\]   Calvete et al. (2012) \[[@B16-toxins-11-00003]\]   

  **Methods**                        C18 rpHPLC,\                             C4 rpHPLC,\                                      C4 rpHPLC,\                                     C18 rpHPLC,\                                   C18 rpHPLC,\                                        C18 rpHPLC,\                                       C18 rpHPLC,\                                       C18 rpHPLC,\
                                     in-solution tryptic digestion, LCMS/MS   in-solution tryptic digestion, LCMS/MS           in-solution tryptic digestion, LCMS/MS          in-gel tryptic digestion, MALDI TOF/TOF        in-solution tryptic digestion, LCMS/MS              in-gel tryptic digestion, MALDI TOF/TOF            in-gel tryptic digestion, LCMS/MS                  N-terminal sequencing, in-gel tryptic digestion, CID-MS/MS

  **3FTX**                           26.33                                    30.44                                            40.43                                           70.5                                           66.14                                               25.3                                               \~49.9                                             81.1

  *SNTX*                             *22.89*                                  *8.33*                                           *20.76*                                         *55.8*                                         *16.94*                                             *25.3*                                             *\~36*                                             *51.7*

  *LNTX*                             *3.44*                                   *22.11*                                          *19.67*                                         *14.7*                                         *48.9*                                              *-*                                                *\~14*                                             *29.4*

  *CTX*                              *-*                                      *-*                                              *-*                                             *-*                                            *0.3*                                                                                                  *-*                                                *-*

  **PLA~2~**                         62.00                                    66.7                                             54.50                                           27.5                                           33.3                                                71.2                                               32.9                                               18.9

  *Acidic*                           *48.26*                                  *57.93*                                          *41.21*                                         *6.1*                                          *0.04*                                              *46.4*                                             *NA*                                               *NA*

  *Basic*                            *13.74*                                  *8.76*                                           *13.28*                                         *21.4*                                         *33.26*                                             *24.8*                                             *NA*                                               *NA*

  *Neutral*                          *-*                                      *0.01*                                           *0.007*                                         *-*                                            *-*                                                 *-*                                                *NA*                                               *NA*

  **CRISP**                          9.00                                     2.53                                             4.95                                            1.3                                            0.05                                                2.5                                                9.1                                                \-

  **LAAO**                           0.18                                     \-                                               \-                                              0.2                                            \-                                                  \-                                                 \-                                                 \-

  **SVMP**                           0.36                                     0.004                                            0.01                                            0.5                                            \-                                                  \-                                                 \~0.9                                              \-

  **NUC**                            \-                                       \-                                               \-                                              \-                                             \-                                                  \-                                                 \~0.8                                              \-

  **CTL**                            \-                                       0.09                                             0.003                                           \-                                             \-                                                  \-                                                 \-                                                 \-

  **PDE**                            0.04                                     \-                                               \-                                              \-                                             \-                                                  \-                                                 \-                                                 \-

  **PLB**                            0.02                                     \-                                               \-                                              \-                                             \-                                                  \-                                                 \-                                                 \-

  **PLA~2~ inhibitor**               0.45                                     0.01                                             \-                                              \-                                             \-                                                  \-                                                 \-                                                 \-

  **OVF**                            0.14                                     \-                                               \-                                              \-                                             \-                                                  \-                                                 \-                                                 \-

  **Waprin**                         0.11                                     \-                                               \-                                              \-                                             \-                                                  \-                                                 \-                                                 \-

  **Non-toxins/cellular proteins**   1.38                                     0.231                                            0.12                                            \-                                             \-                                                  0.2                                                5.0                                                \-

  **Unknown**                        \-                                       \-                                               \-                                              \-                                             0.57                                                0.8                                                1.4                                                \-
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: LD~50~: median lethal dose; i.v.: intravenous; i.p.: intraperitoneal; rpHPLC: reverse-phase high performance liquid chromatography; LCMS/MS: Liquid chromatography-tandem mass spectrometry; MALDI TOF/TOF: Matrix assisted laser desorption/ionization-time of flight tandem mass spectrometry; CID-MS/MS: Collision-induced dissociation-tandem mass spectrometry; 3FTX: three-finger toxin; SNTX: Short alpha-neurotoxin; LNTX: Long alpha-neurotoxin; CTX: Cytotoxin; PLA~2~: Phospholipase A~2~; CRISP: Cysteine-rich secretory protein; LAAO: [l]{.smallcaps}-amino acid oxidase; SVMP: Snake venom metalloproteinase; NUC: Nucleotidase; CTL: C-type lectin; PDE: Phosphodiesterase; PLB: Phospholipase B; OVF: Ophiophagus venom factor. NA: Not available.

toxins-11-00003-t004_Table 4

###### 

Efficacy and potency of Seqirus Sea Snake Antivenom (SSAV) in cross-neutralizing the lethal effect of *Hydrophis curtus* venom and toxin fractions.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Venom/Fraction   Challenge Dose   i.v. LD~50~ (µg/g) ^a^   ED~50~ (µL) ^b^   ER~50~ (mg/mL) ^c^   Potency, P (mg/mL) ^d^   SSAV Protein Concentration (mg/mL)   Normalized P, n-P (mg/g) ^e^
  ---------------- ---------------- ------------------------ ----------------- -------------------- ------------------------ ------------------------------------ ------------------------------
  Venom            5                0.20\                    9.87\             2.53\                2.03\                    217.2 ± 3.0                          9.35
                                    (0.18--0.24)             (7.98--12.21)     (2.28--3.04)         (1.83--2.43)                                                  

  F1_SNTx          5                0.10\                    25.82\            0.41\                0.34\                    217.2 ± 3.0                          1.57
                                    (0.08--0.12)             (22.38--29.79)    (0.34--0.51)         (0.27--0.41)                                                  

  F3_LNTx          5                0.24\                    27.90\            0.95\                0.76\                    217.2 ± 3.0                          3.50
                                    (0.21--0.28)             (25.36--30.70)    (0.83--1.10)         (0.66--0.88)                                                  

  F5               \-               \>1                      \-                \-                   \-                       \-                                   \-

  F6               \-               \>1                      \-                \-                   \-                       \-                                   \-

  F9               \-               \>1                      \-                \-                   \-                       \-                                   \-
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LD~50~: Median lethal dose; ED~50~: Median effective dose; ER~50~: Median effective ratio; ^a^ Median lethal dose was defined as the dose of venom (µg/mL) at which 50% of mice died. ^b^ Median effective dose was defined as the dose of antivenom (µL) at which 50% of mice survived. ^c^ Median effective ratio was defined as the ratio of venom (mg) to the volume does of antivenom (mL) at which 50% of mice survived. ^d^ Potency, P, the neutralization potency of antivenom (mg/mL) was defined as the amount of venom (mg) that was completely neutralized by one mL of antivenom. ^e^ Normalized P, n-P was defined as the neutralization potency of the antivenom in mg venom/g antivenom.
